Pcv76 - Cost-Effectiveness Analysis of Rivaroxaban in the Secondary Prevention of Acute Coronary Syndromes in Greece
Value in Health - United Kingdom
doi 10.1016/j.jval.2018.09.622
Full Text
Open PDFAbstract
Available in full text
Date
October 1, 2018
Authors
Publisher
Elsevier BV